Literature DB >> 28025765

Incidence of malignant mesothelioma in Germany 2009-2013.

Martin Lehnert1, Klaus Kraywinkel2, Evelyn Heinze3, Thorsten Wiethege3, Georg Johnen3, Julia Fiebig2, Thomas Brüning3, Dirk Taeger3.   

Abstract

PURPOSE: The malignant mesothelioma is a rare malignancy and mainly caused by occupational exposure to asbestos. German cancer registries are providing a national database to investigate temporal and regional patterns of mesothelioma incidence. These may be of interest for healthcare planning and for surveillance programs aiming at the formerly exposed workforce.
METHODS: We analyzed population-based incidence data of malignant mesothelioma by site, type, sex, age, as well as district and state of patient's residence. Age-standardized incidence rates (AIRs40+) were calculated according to the European standard population truncated to the age of 40 years and older. We present rates at national, state, and district level and trends of incidence of northern states of Germany.
RESULTS: In total, 7,547 malignant mesotheliomas were reported to German cancer registries diagnosed between 2009 and 2013-90% located to the pleura. On average, 1,198 men and 312 women were affected each year. We estimated AIR40+ of 4.77 in 100,000 German men and 0.98 in 100,000 German women. Regional clusters were predominantly located to the seaports of West Germany. The highest regional AIR40+ was 20 per 100,000 men. Corresponding rates in northeast Germany were between 2 and 4 per 100,000 men.
CONCLUSION: Regional clusters of high incidence indicate districts with former shipyards and steel industry, but predominantly in the western part of Germany. The West-to-East difference corresponds to patterns of mortality. Twenty years after banning asbestos in Germany, Bremen and Hamburg are presenting the highest mesothelioma incidence but show steadily decreasing trends.

Entities:  

Keywords:  Asbestos; Germany; Incidence; Mesothelioma

Mesh:

Substances:

Year:  2016        PMID: 28025765     DOI: 10.1007/s10552-016-0838-y

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  12 in total

1.  Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Authors:  Miklos Acs; Michael Gerken; Ivana Gajic; Max Mayr; Jozef Zustin; Pompiliu Piso
Journal:  Langenbecks Arch Surg       Date:  2022-06-23       Impact factor: 3.445

2.  Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.

Authors:  David B Chapel; Jason L Hornick; Julianne Barlow; Raphael Bueno; Lynette M Sholl
Journal:  Mod Pathol       Date:  2022-04-22       Impact factor: 8.209

3.  [Mesothelioma].

Authors:  I Tischoff; A Tannapfel
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

4.  Incidence of Esophageal Cancer in Iran, a Population-Based Study: 2001-2015.

Authors:  Rahmatollah Moradzadeh; Parvaneh Golmohammadi; Bahman Ghaitasi; Haidar Nadrian; Athareh Najafi
Journal:  J Gastrointest Cancer       Date:  2019-09

5.  Determinants of plasma calretinin in patients with malignant pleural mesothelioma.

Authors:  Martin Lehnert; Daniel G Weber; Dirk Taeger; Irina Raiko; Jens Kollmeier; Susann Stephan-Falkenau; Thomas Brüning; Georg Johnen
Journal:  BMC Res Notes       Date:  2020-07-29

Review 6.  Oncolytic Viral Therapy for Mesothelioma.

Authors:  Daniel F Pease; Robert A Kratzke
Journal:  Front Oncol       Date:  2017-08-24       Impact factor: 6.244

7.  Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial).

Authors:  Duneesha de Fonseka; Wendy Underwood; Louise Stadon; Najib Rahman; Anthony Edey; Chris Rogers; Nick A Maskell
Journal:  BMJ Open Respir Res       Date:  2018-02-19

8.  Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study.

Authors:  Swaantje Casjens; Daniel G Weber; Georg Johnen; Irina Raiko; Dirk Taeger; Carmen Meinig; Susanne Moebus; Karl-Heinz Jöckel; Thomas Brüning; Beate Pesch
Journal:  BMJ Open       Date:  2017-10-11       Impact factor: 2.692

9.  Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers.

Authors:  Georg Johnen; Katarzyna Burek; Irina Raiko; Katharina Wichert; Beate Pesch; Daniel G Weber; Martin Lehnert; Swaantje Casjens; Olaf Hagemeyer; Dirk Taeger; Thomas Brüning
Journal:  Sci Rep       Date:  2018-09-25       Impact factor: 4.379

10.  International Analysis of Age-Specific Mortality Rates From Mesothelioma on the Basis of the International Classification of Diseases, 10th Revision.

Authors:  Paolo Boffetta; Matteo Malvezzi; Enrico Pira; Eva Negri; Carlo La Vecchia
Journal:  J Glob Oncol       Date:  2017-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.